Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFUS-949 Multiple Ascending Dose Study in Healthy Chinese Participants
NCT07676357Phase 1Active, not recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RFUS-949 in acute pain and chronic pain (5 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Adverse Events, Maximum Plasma Concentration and 1 more. Started Jan 2026; status: active, not recruiting.
02
Drugs
RFUS-949
03
Conditions
acute painchronic pain
Beyond the preview
Go deeper on NCT07676357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07676357.